| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L611657-5mg |
5mg |
期货  |
| |
| L611657-25mg |
25mg |
期货 |
|
| 别名 | example 2 [US11001596B2];LY-3410738 |
|---|---|
| 英文别名 | example 2 [US11001596B2];LY-3410738 |
| 规格或纯度 | Moligand™ |
| 英文名称 | LY3410738 |
| 作用类型 | 抑制剂 |
| 作用机制 | 异柠檬酸脱氢酶抑制剂（NADP(+)1;异柠檬酸脱氢酶（NADP(+) ）抑制剂 2 |
| IIUPAC Name | 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one |
|---|---|
| INCHI | 1S/C28H36N6O3/c1-4-25(35)33-14-12-32(13-15-33)24(16-20-6-7-20)22-10-8-21(9-11-22)19(3)30-27-29-17-23-18-37-28(36)34(5-2)26(23)31-27/h4,8-11,17,19-20,24H,1,5-7,12-16,18H2,2-3H3,(H,29,30,31)/t19-,24-/m0/s1 |
| InChi Key | AFGYODUJVVOZAX-CYFREDJKSA-N |
| Smiles | CCN1c2nc(ncc2COC1=O)N[C@@H](C)c1ccc(cc1)[C@H](CC1CC1)N1CCN(CC1)C(=O)C=C |
| PubChem CID | 135125140 |
| 1. Cleary JM, Rouaisnel B, Daina A, Raghavan S, Roller LA, Huffman BM, Singh H, Wen PY, Bardeesy N, Zoete V et al.. (2022) Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.. NPJ Precis Oncol, 6 (1): (61). [PMID:36056177] |
首页
400-620-6333
